Senseonics Stock Earnings Reports

Senseonics reported a strong start to 2026 with Q1 revenue of $11.7 million (up 85% YoY) and a 58% gross margin, driven by direct control of the U.S. commercial organization, higher mix of bundled-pay reimbursements, growing direct-to-consumer (DTC) performance, and scaling of the Eon Care insertion network. Management raised full-year 2026 revenue guidance to $60–64 million (70%–82% YoY growth) and expects full-year gross margins of 55%–58%, with seasonality skewed to the second half of the year. The company completed financing actions that added >$100 million of growth capital (a $92M equity offering and a Hercules credit facility increase and draw), believes it has sufficient capital to advance its pipeline (Gemini targeted for H1 2027; Freedom first-in-human trial planned H2 2026), and is investing heavily in DTC (~$13M planned for 2026) and in scaling the commercial organization and Eon Care. OpEx and cash burn will increase as commercial capabilities are internalized: operating expenses are expected to be $150M–$160M and 2026 cash usage $110M–$120M. Management emphasized that integration of the Ascensia commercial team has been smooth in the U.S., improved alignment across commercialization, manufacturing and product development, and that uptake and retention metrics for the year‑long Eversense 365 remain encouraging.